medigraphic.com
ISSN 1561-3046 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cub Med Mil 2014; 43 (2)

Bacterial growth in diabetic foot ulcer prior to Heberprot-P

Pérez RS, Díaz MA, González DCA, García GY

Language: Spanish
References: 19
Page: 169-175
PDF size: 76.07 Kb.


ABSTRACT

Objective: to determine the microbiological growth behavior in diabetic foot ulcers, pre Heberprot-P.
Methods: descriptive study was conducted by reviewing the medical records of 52 patients enrolled in Heberprot-P clinical trials phase I and II of diabetic foot ulcer. 63 samples were taken and microbiological study was considered at any point in its evolution in the study period.
Results: four samples were negative and 29 positive to Staphylococcus aureus meticillin resistant, which was the most frequently cultivated germ, so that one third of the patients required antibiotic treatment.
Conclusions: microbiological study is recommended to all patients with diabetic foot ulcer, prior to the use of Heberprot-P even when there is no clinical evidence of local infection.


REFERENCES

  1. Colectivo de autores. Programa Nacional de Diabetes mellitus. La Habana: MINSAP; 2002.

  2. Rosenblum BL, Pomposelli FB, Giurini JM, Gibbson GW, Freeman DV, Chrzan JJ, et al. Maximizing foot savage by combined approach to foot ischemia and neuropathy ulceration in patients with diabetes. Diabetes Care. 1994;17:983-7.

  3. Young MJ, Breddy JL, Veves A, Bulton AJM. The prediction of diabetic neuropathy foot ulcerations using vibration perception threshold. Diabetes Care. 1994;17:1-4.

  4. Connor H. The economic impact of diabetic. In: Connor H, Boulton AJM. The foot in diabetic chescheste. England: Wiley and Sons; 1987. p. 145-9.

  5. Lo Presti Gentile A. Diagnóstico y tratamiento del pie diabético. Caracas: Universidad de Los Andes, Facultad de Medicina; 2002.

  6. Gregory MC, Cavanach PR, Jans S, Ulbrecht TB, Gibbson GW. Assessment and management of foot disease in patient with diabetic. New Engl J Med. 1994;331(13):29.

  7. Bennsh AK. The etiology of diabetic neuropathic ulceration of the foot. Surgery. 1985;72:1-6.

  8. Baynes JW. Perspectives in diabetic role of oxidative stress development of complications in diabetic. Diabetes. 1993;40:405-11.

  9. Hall JB, Scmdt GA, Wood LDH. Principles of critical care. International Edition. New York: McGraw-Hill, Inc.; 1992. p.1324-34.

  10. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7(3):178-82.

  11. Naimi TS. Comparison of community-and health care-associated methicillinresistant Staphylococcus aureus infection. JAMA. 2003;290(5):2976-84.

  12. Cerda E. La vigilancia de la infección nosocomial en las UCIs. La experiencia del sistema ENVIN simplificado. Enf Infecc Microbiol Clin. 2004;22(1):123.

  13. Álvarez Lerma F, Palomar Martínez M. Decálogo de normas en la utilización de antibióticos en pacientes críticos. Med Int. 2000;24:69-77.

  14. Hernández M, Rodríguez ZR, González S, Cruz CR, Fernández JE. Staphylococcus aureus, una causa frecuente de infección nosocomial. Rev Méd Elect [Internet]. 2005 [citado 12 Dic 2012];27(5). Disponible en: http://www.revmatanzas.sld.cu/revista%20medica/ano%202005/vol5%202005/tema 08.htm

  15. Hughes CM, Smith MBH, Tunney MM. Estrategias de control de infecciones para la prevención de la transmisión del Staphylococcus aureus resistente a la meticilina (SARM) en centros de cuidado para personas mayores. Biblioteca Cochrane Plus [Internet]. 2011 [citado 12 Dic 2012]. Disponible en: http://www.updatesoftware. com/BCP/BCPGetDocument.asp?DocumentID=CD006354

  16. Oto MA, Pinto ME, Martínez V, Fabio C, Soza M, Jerez R, et al. Control de infecciones por Staphylococcus aureus resistente a meticilina en una unidad de neonatología. Rev Chil Pediatr. 1992;63(3);134-8.

  17. Palacio R, Alonso R, Romero S, Bazet C. Costos de infecciones intrahospitalarias por Staphylococcus aureus; meticilin resistente vs. meticilin sensible. Rev Panamer Infect [Internet]. 2006 [citado 12 Dic 2012];8(1). Disponible en: http://www.revistaapi. com/1%20edicao%202006/pg/art_04_0106.html

  18. Echevarria Zarate J, Iglesias Quilca D. Estafilococo Meticilin resistente, un problema actual en la emergencia de resistencia entre los Gram positivos. Rev Med Hered. 2003;14(4):197.

  19. Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, et al Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect. 2006;63S:S1-S44.




2020     |     www.medigraphic.com